Clinical trial NCT05687461: Construction of a National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases
Official title: Construction of a National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases and Technical Promotion of Standardized Diagnosis and Treatment Programs
Study type: OBSERVATIONAL
Overall status: ACTIVE_NOT_RECRUITING
Conditions: Quality Control
Keywords: Quality Control
Respiratory Diseases
Lead sponsor: China-Japan Friendship Hospital
Sponsor class: OTHER
First posted: 2023-01-18
Enrollment: 10000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: OTHER
Sampling method: PROBABILITY_SAMPLE
Study population: People at high risk of VTE, people diagnosed with VTE

Brief summary: 1. Build a national diagnosis and treatment quality control platform for major respiratory diseases It will establish and improved a "National diagnosis and Treatment quality control Platform for major respiratory diseases", and form a three-level network of diagnosis and treatment quality control for major respiratory diseases with a three-level system structure of "national, provincial and hospital".
2. Promote standardized diagnosis and treatment techniques for major respiratory diseases Relying on the specialized disease collaboration group or innovative unit model, all-round and hierarchical precision training and teaching are carried out to popularize and promote standardized diagnosis and treatment technology schemes for major respiratory diseases, so as to achieve the homogenization of diagnosis and treatment level for major respiratory diseases.

Detailed description: 1. Build a national diagnosis and treatment quality control platform for major respiratory diseases Cooperate with the Medical Administration Administration of the National Health Commission, the Medical Administration Institute of the National Health Commission and the National Center for Respiratory Disease Medical Quality Control to integrate the existing diagnosis and treatment quality indicators and data from NCIS (National Medical Quality Management and Control Information Network) and HQMS (Hospital Quality Monitoring System), and determine the definition, data sources and collection rules of core quality control indicators. It has established and improved a "National diagnosis and Treatment quality control Platform for major respiratory diseases", and formed a three-level network of diagnosis and treatment quality control for major respiratory diseases with a three-level system structure of "national, provincial and hospital".
2. To master the incidence trend and diagnosis and treatment quality of major respiratory diseases Through the big data integration and analysis function of the "National Diagnosis and Treatment Quality Control Platform for Major Respiratory Diseases", the incidence trend and law of various major respiratory diseases are mastered. To understand the difference in the diagnosis and treatment quality of respiratory diseases in hospitals of different regions and levels, including the allocation of related resources (such as personnel, technology, equipment, information construction, etc.); The status of diagnosis and treatment ability (prevention, diagnosis, treatment, rehabilitation, etc.); Current burden of disease (e.g. morbidity, case fatality rate, average length of stay, average cost of stay, etc.)
3. Promote standardized diagnosis and treatment techniques for major respiratory diseases Relying on the specialized disease collaboration group or innovative unit model, through online and offline academic conferences, continuing medical education, specialized training, visits and exchanges, case discussions, knowledge competitions, wechat public accounts and other new media means, regularly focus on "prevention, diagnosis, treatment, rehabilitation, management, quality control" and many other aspects. Comprehensive and hierarchical precision training and teaching should be carried out to popularize and promote standardized diagnosis and treatment technology schemes for major respiratory diseases, so as to achieve the homogenization of diagnosis and treatment levels for major respiratory diseases.

Eligibility criteria: Inclusion Criteria:

I. For patients at high risk for VTE 1) Have an expected hospital stay of ≥72 hours for medical and/or surgical treatment II. For patients diagnosed with VTE

1) With clearly diagnosed of deep vein thrombosis or pulmonary thromboembolism

Exclusion Criteria:

I. For patients at high risk for VTE

1. VTE identified on CTPA or lower extremity vein ultrasound at or any time before enrollment
2. Requiring a full dose of anticoagulant treatment before enrollment (e.g., recent VTE, atrial fibrillation).

Primary outcomes:
measure: A respiratory quality control network platform has been established
timeFrame: 2025.01
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: China-Japanese Friendship Hosptial
state: Beijing
Study officials:
affiliation: Department of Respiratory and Critical Care Medicine
name: Zhai Zhenguo, Doctor
role: PRINCIPAL_INVESTIGATOR
References: